03/13/25 -Epirium Bio to Present MF-300 Preclinical Data at the International Conference on Frailty and Sarcopenia Research
01/30/25 – Epirium Bio Announces First Participants Dosed in Phase I Clinical Trial Evaluating MF-300 for the Treatment of Sarcopenia
12/23/24 – Epirium Bio Announces FDA Clearance of IND Application for MF-300 and Appointment of Alex Casdin as New CEO and Russell Cox as Executive Chairman
11/13/24 – Epirium Bio Presented Late-Breaking Preclinical Data of MF-300 (15-PGDH Enzyme Inhibitor) at the Gerontological Society of America Annual Scientific Meeting 2024
Archived Press Releases